Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTK HealthcareBOM:507747 -4.34%72 Return-on-Tangible-Equity is 7.81% as of Mar. 2026, which is 20% below its 10-year median of 9.71. GuruFocus rates BOM:507747 with a GF Score™ of 72/100 and a GF Value™ of ₹1,458.76 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 901 Drug Manufacturers companies, TTK Healthcare ranks worse than 55.49% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. TTK Healthcare's annualized net income for the quarter that ended in Mar. 2026 was ₹870 Mil. TTK Healthcare's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹11,149 Mil. Therefore, TTK Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 7.81%.
The historical rank and industry rank for TTK Healthcare's Return-on-Tangible-Equity or its related term are showing as below:
BOM:507747'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.93 Med: 9.71 Max: 99.73
Current: 6.04
During the past 13 years, TTK Healthcare's highest Return-on-Tangible-Equity was 99.73%. The lowest was 4.93%. And the median was 9.71%.
BOM:507747's Return-on-Tangible-Equity is ranked worse than 55.49% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs BOM:507747: 6.04
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
TTK Healthcare Return-on-Tangible-Equity Related Terms
TTK Healthcare Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for TTK Healthcare's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:507747 vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, TTK Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTK Healthcare Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTK Healthcare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where TTK Healthcare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 7.81% mean?
TTK Healthcare (BOM:507747) has a Return-on-Tangible-Equity of 7.81% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TTK Healthcare and its competitors. This is 20% below median its historical median of 9.71. Over the past decade, TTK Healthcare's Return-on-Tangible-Equity has ranged from 4.93 to 99.73. According to the industry distribution chart, TTK Healthcare ranks #500 out of 901 companies in the Drug Manufacturers industry, placing it in the top 55.5%.
Is TTK Healthcare's Return-on-Tangible-Equity too high?
TTK Healthcare's current Return-on-Tangible-Equity of 7.81% is 20% below median its 10-year median of 9.71. Over the past 10 years, this metric has ranged from a low of 4.93 to a high of 99.73. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. TTK Healthcare's value of 7.81% is 1% below this industry median. Based on the distribution chart, TTK Healthcare ranks #500 out of 901 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, TTK Healthcare has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTK Healthcare's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, TTK Healthcare ranks #500 out of 901 companies for Return-on-Tangible-Equity. This places TTK Healthcare in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.89. TTK Healthcare's value of 7.81% is 1% below this benchmark. Historically, TTK Healthcare's own Return-on-Tangible-Equity has ranged from 4.93 to 99.73 over the past decade. While the company's 10-year median is 9.71 vs. the industry median of 7.89, TTK Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTK Healthcare's current Return-on-Tangible-Equity of 7.81% is 1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TTK Healthcare and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTK Healthcare's current Return-on-Tangible-Equity is 7.81%, which is 20% below median its own 10-year median of 9.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTK Healthcare stock overvalued right now?
Based on GuruFocus' analysis, TTK Healthcare (BOM:507747) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹1,458.76, compared to a current price of ₹1,001.90 — trading 31.3% below its estimated fair value. The current Return-on-Tangible-Equity is 7.81%, which is 20% below median its 10-year median of 9.71 and 1% below the Drug Manufacturers industry median of 7.89. TTK Healthcare's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For TTK Healthcare (BOM:507747), the current Return-on-Tangible-Equity is 7.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTK Healthcare (BOM:507747) Overvalued in 2026?
Based on GuruFocus' analysis, TTK Healthcare stock appears to be undervalued.
The current stock price of ₹1,001.90 is trading 31.3% below its estimated GF Value™ of ₹1,458.76.
GuruFocus considers TTK Healthcare to be Significantly Undervalued.
Key valuation signals for BOM:507747:
Return-on-Tangible-Equity: 7.81% (20% below median its 10-year median of 9.71)
GF Value™: ₹1,458.76 vs. price of ₹1,001.90 (31.3% below fair value)
Industry Position: 1% below the Drug Manufacturers median (#500 of 901)
No single metric tells the full story. See the BOM:507747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTK Healthcare Ltd is an Indian pharmaceutical company. The company's operating segment includes Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods Division, and Others. Its Animal Welfare segment includes products for both Human and Veterinary use. The Consumer Products comprises of marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners and others. Protective Devices comprises of manufacturing and marketing of Male Contraceptives and other allied products. It generates maximum revenue from the Pharmaceuticals segment. Geographically, it derives a majority of revenue from India.
72GF Score
Get the complete analysis for BOM:507747
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507747 has been successfully added to your 
